In Brief: FSMA Rules Proposed | One-Step Exclusivity | Early At CHPA | EU Clears NovaTears
This article was originally published in The Tan Sheet
FSMA auditing, supplier verification rules proposed; Plan B One-Step gets OTC exclusivity until 2016; Early joins CHPA as VP, CFO; Novaliq’s NovaTears Gains EU approval; and Senate bill boosts NIH appropriation.
You may also be interested in...
The Center for Reproductive Rights and other plaintiffs suing FDA say the agency’s plan to approve only Teva’s Plan B One-Step for universal OTC sales, but not less-expensive generic emergency contraceptives, would not provide sufficient access for all women.
FDA Center for Food Safety and Applied Nutrition Director Michael Landa says rules for preventive controls for human food and the foreign supplier verification program are “in the final stages of review.” However, the rule for accreditation of third-party inspectors is stalled.
Amneal has become the first company to secure US approval for, and to launch, a generic alternative to Merck & Co’s top-selling, off-patent NuvaRing contraceptive device in the US. Other generics developers appear to be several months behind.